Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
- Conditions
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02061865
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01997164
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01979016
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 253
- Registration Number
- NCT01963598
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2733
- Registration Number
- NCT01949311
- Locations
- 🇵🇱
Regeneron Study Site 5, Warszawa, Mazowieckie, Poland
🇪🇸Regeneron Study Site 4, Barcelona, Spain
🇬🇧Regeneron Study Site 1, London, United Kingdom
An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01933763
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
- Conditions
- Interventions
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 803
- Registration Number
- NCT01926782
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01922661
Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT01910220
Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT01893528